Glaukos Corp (NYSE:GKOS) reported mixed results for the fourth quarter on Tuesday.
The company posted quarterly losses of 28 cents per share which missed the analyst consensus estimate of losses of 20 cents per share. The company reported quarterly sales of $143.100 million which beat the analyst consensus estimate of $136.396 million.
Glaukos affirmed FY2026 sales guidance of $600.000 million to $620.000 million.
“Our record fourth quarter results cap off a highly successful year of global execution across our key commercial and development initiatives, leaving us well positioned to sustain our strong growth momentum in 2026 and beyond driven by two transformational growth drivers in iDose TR and now Epioxa,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Glaukos shares fell 0.1% to trade at $106.64 on Wednesday.
These analysts made changes to their price targets on Glaukos following earnings announcement.
- Needham analyst David Saxon maintained Glaukos with a Buy and raised the price target from $125 to $127.
- Wells Fargo analyst Larry Biegelsen maintained the stock with an Overweight rating and raised the price target from $122 to $135.
Considering buying CL stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments